Innoviva (INVA): H.C. Wainwright sees 113% upside potential - Royalties from franchise products in the field of respiratory diseases offer potential!
Reading Time: 3 minutes
Innoviva Inc. (INFA) operates with a diversified portfolio consisting of two main pillars: a stable licensing business and a growing specialty therapeutics platform (Innoviva Specialty Therapeutics, IST). The licensing business is based on the widely used respiratory products RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, marketed by GSK, generating a robust, steady revenue stream. In the fiscal year ending March 31, 2025, licensing revenues of $207 million were generated from RELVAR®/BREO® ELLIPTA® and $48 million from ANORO® ELLIPTA®....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
